905 results about "Nucleoside" patented technology

The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells. The contiguous nucleotide sequence of the antisense oligonucleotides comprise 2′-O-methoxyethyl-RNA (2′-MOE) nucleosides and the antisense oligonucleotides are attached to cholesterol moieties.

The invention relates to an external composition for hair growth regulation and a preparation method thereof, and belongs to the technical field of cosmetics and medicines. The composition disclosed by the invention comprises nano mesoporous carbon for enhancing permeation, various surface functional modifications on the nano mesoporous carbon, minoxidil, protein fragments, polypeptides, oligopeptides, amino acids, dutasteride, bimatoprost, traditional Chinese medicine extracts, vitamins, caffeine, nucleosides, growth factors and various auxiliary functional components. Wherein the pore diameter of mesopores of the nano mesoporous carbon for enhancing permeation is 2-30 nm, the total pore volume of the mesopores is 1.5-3.5 cm < 3 > / g, and the particle size of the nano mesoporous carbon is 50-200 nm. The prepared nano mesoporous carbon is granular, controllable in size, stable in structure, free of irritation to skin, capable of keeping inert to various active ingredients in the composition, capable of enhancing absorption and permeation of other ingredients on the skin, wide in application range, capable of compounding various types of active ingredients and high in biological safety.

The technology described herein relates to 5'-modified nucleosides, nucleotides, oligonucleotides and double-stranded RNAs, e.g., siRNAs, and kits comprising them and methods of their use for inhibiting target genes.

Methods for treating itch in human patients with atopic dermatitis (AD) and / or prurigo nodularis (PN) comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3- yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

The invention discloses a method for screening a non-natural nucleic acid aptamer of targeted thrombin based on streptavidin magnetic beads and application, and belongs to the technical field of biology. According to the method, an initial screening library is efficiently constructed through a primer extension technology, and a chemical modification SELEX technical process is simplified; a streptavidin magnetic bead separation technology is introduced, so that the screening specificity and efficiency are improved, the screening period is remarkably shortened, and the cost is reduced; by selecting non-natural nucleic acid modification sites and adopting a strategy of combining reverse screening and forward screening, high specificity and affinity of the aptamer are ensured, and limitation of an existing screening method is overcome; the screened non-natural nucleic acid aptamer shows high affinity and excellent stability, the aptamer with a specific structure and function is successfully obtained by optimizing the proportion of nucleoside triphosphate monomers and extension reaction conditions, and a wide application prospect is provided for the fields of drug development, biosensor preparation and the like. A new path is opened up for research and application of the nucleic acid aptamer.

The invention relates to the field of microorganisms, and discloses a Lactococcus lactis subsp. Lactis VB346 which is preserved in the China Center for Type Culture Collection on September 20, 2024, and the preservation number is CCTCC NO: M 20242013. The invention further discloses a preparation method of the Lactococcus lactis subsp. Lactis VB346. The lactococcus lactis subsp. Lactis VB346 disclosed by the invention has the capability of efficiently degrading purine nucleoside, and can decompose purine nucleoside in ingested food in intestinal tracts, so that the absorption amount of purine nucleoside by small intestines is reduced. The polypeptide has the ability of degrading bilirubin, and can be used for treating or improving hyperbilirubinemia, or improving liver and gall injury caused by hyperbilirubin; meanwhile, the acid resistance required by survival in the stomach, the cholate tolerance required by survival in the intestinal tract and the stable survival ability in the intestinal tract are achieved, and the bacillus subtilis has huge application prospects in preparation of drugs, microbial agents, health care products or food.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The present application relates to single-stranded or double-stranded interfering RNA molecules (e.g., siRNAs) that target the alpha synuclein (SNCA) gene. The interfering RNA molecule may contain a specific pattern of nucleoside modification and inter-nucleoside linkage modification as a pharmaceutical composition comprising the interfering RNA molecule. The siRNA molecule may be a branched siRNA molecule, such as a two-branched, three-branched or four-branched siRNA molecule. The disclosed siRNA molecules may also be characterized by a 5 '-phosphorus stabilizing moiety and / or a hydrophobic moiety. In addition, the present disclosure provides methods for delivering siRNA molecules of the present disclosure to a subject, such as the central nervous system of a subject identified as having synucleinopathies.

The invention belongs to the technical field of flame retardance and antibiosis, and particularly relates to a flame-retardant and antibiosis composition for bamboos, flame-retardant and antibiosis bamboos, a preparation method and application, the flame-retardant and antibiosis composition for bamboos comprises the following components by weight: 5-8% of ammonium phosphate, 5-8% of nucleoside phosphate, 3-5% of phytic acid or phytate, 3-6% of urea, 1-3% of amino acid, and 8-12% of a hydroxyl-containing material; and the balance of water. The hydroxyl-containing material is one or more of soluble nano cellulose, a Tris reagent, sorbitol and erythritol; on the basis of keeping the original color of the bamboo, the flame-retardant and antibacterial effects of the bamboo are improved.

The present disclosure describes novel reagents and processes for preparing oligonucleotides, which have two or more nucleotides. In one embodiment, the reagent is represented by Formula I. wherein: W is O or NH; R1 is -H or a solid support; R2 is a silyl hydroxyl protecting group or an alloc protecting group, R3 is a nucleoside or a group represented by (II) wherein (III) represents the point of attachment for R3.

Provided is a method for preparing purine nucleoside. The preparation method comprises catalyzing a uridine substrate and a substrate base by using a pyrimidine nucleoside phosphorylase and a purine nucleoside phosphorylase, and preparing and obtaining purine nucleoside. The uridine substrate comprises uridine, 2'-deoxyuridine or 2'-amino-2'-deoxyuridine, and the substrate base comprises a purine compound, wherein on the purine compound, R1 comprises -NH 2,-OCH 3 or -Cl, and R2 comprises -NH 2, -F or -Cl. The preparation method can solve the problem of low yield in the preparation of nucleoside compounds in the prior art, and is suitable for the field of enzymatic catalysis.

The invention discloses a symmetric nucleoside microneedle patch loaded with polymer vesicles as well as a preparation method and application of the symmetric nucleoside microneedle patch. The symmetric nucleoside microneedle patch loaded with the polymer vesicles comprises a guanosine-quadruplex hydrogel microneedle tip doped with drug-loading polymer vesicles, the raw material of the drug-loaded polymer vesicle comprises a polycaprolactone-polyglutamic acid copolymer; the guanosine-quadruplex hydrogel is prepared from the following raw materials: guanosine and KB (OH) 4. The microneedle patch is constructed on the basis of dynamic covalent bond and non-covalent interaction, has a sharp tip array capable of penetrating the epithelium and the lower layer of a mucous membrane, can efficiently deliver a drug to a canker lesion part by bypassing a mucous membrane barrier, can be controllably broken under a high ROS condition of an inflammation microenvironment, has the characteristics of high drug delivery efficiency and high accuracy, and can be used for preparing a medicine for treating the canker lesion part. The effect of effectively improving chemotherapy-induced oral ulceration can be achieved by reducing inflammatory response, relieving pain feeling and inhibiting pain sensitization.

The invention discloses a saccharomycetes lysate, a preparation method and application, and the main components of the saccharomycetes lysate comprise the following components accounting for the relative content of the saccharomycetes lysate: 93-98% of nucleoside, nucleotide and derivatives thereof; and 0.2 to 6% of amino acid; wherein the nucleoside, the nucleotide and the derivatives of the nucleoside and the nucleotide comprise one or more of adenosine, succinyladenosine, adenosine-3 '-phosphoric acid, inosine and S-adenosine homocysteine. Effect evaluation is carried out on the saccharomycetes lysate, and verification shows that the saccharomycetes lysate has the effects of whitening, repairing skin injury, preventing light and aging, resisting pollution and oxidation, resisting inflammation and relieving, protecting hair and preventing hair loss, replenishing water and preserving moisture, and enhancing skin vitality or removing dark circles.

The invention discloses a gelatinized and / or micronized nucleoside drug and a preparation method thereof, and belongs to the technical field of drugs. The preparation method comprises the following steps: mixing lipoic acid, a nucleoside drug and an esterification catalyst, carrying out a grafting reaction in a reaction solvent to obtain a lipoic acid grafted nucleoside drug, dispersing the lipoic acid grafted nucleoside drug in an organic solvent to obtain a dispersion liquid, dropwise adding the dispersion liquid into hot water, and carrying out ring opening polymerization to obtain the lipoic acid grafted nucleoside drug. The nucleoside drug nanogel, nanoparticle or nanofiber is obtained, and the structure and performance improvement based on the drug itself is realized. The gelated and / or micronized nucleoside medicine prepared by the invention has obviously improved scavenging rates of DPPH free radicals and ABTS free radicals, and the method can improve the oxidation resistance of the nucleoside medicine and has the characteristic of improving the stability and functionality of the medicine.

The invention discloses a synthesis method of 2 '-fluoro-2'-deoxyguanosine. According to the method, thymine nucleoside phosphorylase and purine nucleoside phosphorylase are used as biocatalysts, and 2 '-fluoro-2'-deoxyuridine and guanine are used as substrates to synthesize the 2 '-fluoro-2'-deoxyguanosine. Compared with a chemical method, the production cost is greatly reduced; meanwhile, the synthesis method can effectively solve the problem that the product is difficult to separate.

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using thereof.

This invention relates to the finding that FAMIN (fatty acid metabolism-immunity nexus; LACC1, C13orf31)) is a trifunctional purine salvage enzyme that displays a unique combination of adenosine deaminase, purine nucleoside phosphorylase and methylthioadenosine phosphorylase activities. Methods of measuring FAMIN activity and screening for FAMIN modulators are provided that comprise determining the adenosine deaminase activity, purine nucleoside phosphorylase activity and / or methylthioadenosine phosphorylase activity of an isolated FAMIN protein.

The invention discloses an escherichia coli recombinant bacterium for whole-cell catalytic synthesis of rebaudioside M as well as a construction method and application of the escherichia coli recombinant bacterium. The Escherichia coli recombinant bacterium for the whole-cell catalytic synthesis of the rebaudioside M, which is constructed by the invention, contains a glycosyl transferase UGT76G1 coding gene mutant, a glycosyl transferase UGT91C1 coding gene mutant, a sucrose synthase atSuS1 gene and a polyphosphoglucokinase cgPPGK gene; a glucose-1-phosphate uridine transferase galU gene, a nucleoside diphosphate kinase ndk gene and a nucleoside diphosphate kinase ndk gene are over-expressed; meanwhile, an encoding gene araA gene of L-arabinose isomerase and an encoding gene ushA gene of 5 '-nucleotidase / UDG hydrolase are knocked out. According to the recombinant escherichia coli constructed by the invention, Reb D is prevented from being directly used as a synthetic substrate, so that the raw materials are easier to obtain, and the conversion rate of the substrate and the synthetic rate and yield of rebaudioside M are remarkably improved.

According to the present invention, the compound represented by the formula I is synthesized through the brand new nucleoside intermediate, the compound represented by the formula I is the important precursor nucleoside # imgabs0 #, and the definition of R1 is as defined in the specification. The preparation method provided by the invention overcomes the defects of more reaction byproducts and low yield in the prior art, and has a better application prospect.

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The present invention is directed to terminal deoxynucleotidyltransferase (TdT) variants that (i) comprise an amino acid sequence that is at least a specified percent identical to an indicated SEQ ID NOs and have at least one substitution at Q455 or at least Q455 plus at least one further substitution at G186, S248, T331, Q390, K394 or H466 (where positions are with respect to SEQ ID NO 1 and functionally equivalent positions in indicated SEQ ID NOs), (ii) are capable of template-free extension of a polynucleotide, and (iii) exhibit enhanced stability or enhanced efficiency in incorporating 3′-0-blocked nucleoside triphosphates into a polynucleotide. The invention is also directed to the use of these TdT variants for synthesizing polynucleotides of any predetermined sequence.

The invention discloses a method for constructing a blood serum endogenous biomarker and a depression diagnosis model of a depression patient, which couples non-targeting and targeting screening technologies, systematically characterizes endogenous small molecule metabolites in blood serum, identifies differential metabolites between the depression patient and a healthy control group, and determines the blood serum endogenous biomarker and the depression diagnosis model of the depression patient. And then determining a biomarker closely related to depression by using a regression model. According to the invention, potential depression biomarkers such as N-methyl-L-alanine, N-acetylneuraminic acid, N-acetylglycine, thymine ribonucleoside, decanoyl carnitine, aspartic acid-phenylalanine and the like are discovered. The diagnosis model obtained by training according to the ratio of N-acetylglycine to thymine ribonucleoside has the highest accuracy (99%), and healthy and disease samples can be effectively distinguished by using a threshold value 2.434. Therefore, the ratio of N-acetylglycine to thymine ribonucleoside is a potential biomarker capable of realizing rapid and accurate diagnosis of depression.

The invention relates to the technical field of microbial metabolism engineering, and discloses a genetically engineered bacterium for high-yield L-histidine as well as a construction method and application of the genetically engineered bacterium. A nucleoside triphosphate pyrophosphate hydrolase coding gene mazG gene and a flagellin synthesis gene flhC gene are knocked out at the same time, an o-aminobenzoic acid phosphoribosyltransferase coding gene trpD gene and a ribulose phosphate 3-isomerase coding gene rpe gene are knocked down, and the recombinant protein is obtained. A ribose-5-phosphate isomerase gene coding rpiA gene and a lysine exponential coding gene lysE gene are overexpressed, and a promoter of 6-phosphoglucose isomerase pgi is replaced by a PfliC promoter, so that key substances for synthesis of L-histidine can be effectively accumulated, the fermentation yield of L-histidine is greatly increased, and compared with an initial strain, the yield of L-histidine is increased by 33.3%.

The invention is directed to methods for synthesizing a plurality of oligonucleotides in the same reaction vessel, and in some embodiments, using the synthesized oligonucleotides in an oligonucleotide-based assay in such reaction vessel. In some embodiments, methods of the invention are implemented by steps of (a) providing a plurality of different initiators attached to one or more supports, each different initiator having a terminal nucleotide with a different 3-O-blocking group; (b) for each different initiator, synthesizing a polynucleotide by repeated cycles of template-free enzymatic additions of 3′-O-blocked nucleoside triphosphates, wherein the blocking group of the 3-O-blocked nucleoside triphosphate is removable under deblocking conditions orthogonal to the deblocking conditions for removing blocking groups of the other initiators; and (c) releasing the oligonucleotides from the polynucleotides and the one or more solid supports.

The present disclosure relates to novel destabilizing molecules, such as a butadiol moiety, modified nucleosides incorporating the butadiol moiety, modified nucleotides incorporating the butadiol moiety, and oligonucleotides and RNAi agents comprising such modified nucleotides that improve selectivity and / or reduce off target effects while maintaining or improving knockdown of on target gene expression.

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.

The invention relates to lactobacillus reuteri SAU-R-8 which is derived from Tibet naturally-fermented sour yak milk and is used for producing exopolysaccharides and application of the lactobacillus reuteri SAU-R-8 in reducing uric acid, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30373, and the preservation date is April 19, 2024. The lactobacillus reuteri SAU-R-8 provided by the invention is screened from yak yogurt naturally fermented from herdsmen in the Sankarst region of Tibet, the yield of exopolysaccharides in an MRS culture medium reaches 318.57 mg / L, nucleoside substances such as inosine and guanosine can be efficiently degraded, purine substances such as guanine can be efficiently absorbed, the activity of xanthine oxidase can be inhibited, and the lactobacillus reuteri SAU-R-8 can be used for preparing the yak yogurt. The method can be further applied to product development for relieving or treating hyperuricemia.

The invention discloses a construction method for improving gene editing efficiency of a recombinant trichoderma reesei engineering strain, and belongs to the technical field of gene editing. In the research, the T.reesei CJ2095 is taken as an original strain, the gene ku80 is knocked out, and the gene editing efficiency is improved to 7.14% from 1.04% of that of a control strain. In order to realize the recycling of the screening marker of the orotidine-5 '-phosphate decarboxylase gene pyr4, the gene pyr4 is knocked out. In addition, homologous recombinase rad51 and rad52 genes of a T.reesei endogenesis are respectively overexpressed, and the overexpressed gene rad52, namely the homologous recombination efficiency of the engineering strain T.reesei CJ2095 delta ku80 delta pyr4: rad52, can be improved to 43.75%, which is 42 times of that of an original strain.